CanSino Biologics (HKSE:06185) EBIT per Share : HK$-8.30 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics EBIT per Share?

CanSino Biologics's EBIT per Share for the three months ended in Mar. 2024 was HK$-0.71. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-8.30.

During the past 3 years, the average EBIT per Share Growth Rate was -59.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CanSino Biologics's EBIT per Share or its related term are showing as below:

HKSE:06185' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -80.3 Med: -68.15 Max: -58.8
Current: -59.8

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of CanSino Biologics was -58.80% per year. The lowest was -80.30% per year. And the median was -68.15% per year.

HKSE:06185's 3-Year EBIT Growth Rate is ranked worse than
96.17% of 862 companies
in the Drug Manufacturers industry
Industry Median: 7.35 vs HKSE:06185: -59.80

CanSino Biologics's EBIT for the three months ended in Mar. 2024 was HK$-174.0 Mil.

CanSino Biologics EBIT per Share Historical Data

The historical data trend for CanSino Biologics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics EBIT per Share Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.86

-2.04

9.69

-5.17

-8.49

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-0.89	-4.67	-0.68	-2.24	-0.71

CanSino Biologics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CanSino Biologics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2094.301	/	246.766
=	-8.49

CanSino Biologics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-174.036	/	246.516
=	-0.71

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-8.30

CanSino Biologics (HKSE:06185) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CanSino Biologics EBIT per Share Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (HKSE:06185) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » EBIT per Share

Traded in Other Exchanges

CASBF:USA CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

Executives

The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Mao Helen Huihua	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2201 Interest of corporation controlled by you
Qm29 Limited	2101 Beneficial owner
Qiu Dongxu	2501 Other
Yu Xuefeng	2501 Other
Zhu Tao
Chao Shou Bai	2202 Interest of your spouse
Orbimed Capital Llc	2102 Investment manager

CanSino Biologics (HKSE:06185) Headlines

No Headlines